These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 24240798)
1. Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia. Nagao T; Takahashi N; Kameoka Y; Noguchi S; Shinohara Y; Ohyagi H; Kume M; Sawada K Intern Med; 2013; 52(22):2567-71. PubMed ID: 24240798 [TBL] [Abstract][Full Text] [Related]
2. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Steinberg M Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072 [TBL] [Abstract][Full Text] [Related]
3. The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms. Amrein PC Leuk Lymphoma; 2011 May; 52(5):754-63. PubMed ID: 21463117 [TBL] [Abstract][Full Text] [Related]
4. Chronic Myelogenous Leukemia Diagnosed in the Setting of Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Viswanathan K; Roboz G; Chadburn A; Mathew S Int J Surg Pathol; 2020 Apr; 28(2):216-224. PubMed ID: 31544558 [TBL] [Abstract][Full Text] [Related]
5. Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells. Larsson N; Billström R; Lilljebjörn H; Lassen C; Richter J; Ekblom M; Fioretos T Cancer Genet Cytogenet; 2010 Jun; 199(2):89-95. PubMed ID: 20471511 [TBL] [Abstract][Full Text] [Related]
6. Dasatinib-induced response in a rare case of chronic lymphocytic leukaemia associated with chronic myeloid leukaemia. Tecchio C; Nichele I; Todeschini G; Pizzolo G; Ambrosetti A Br J Haematol; 2009 Jul; 146(2):222-3. PubMed ID: 19466973 [No Abstract] [Full Text] [Related]
7. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia]. Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902 [TBL] [Abstract][Full Text] [Related]
8. [A case of chronic myeloid leukemia occurring during treatment for chronic lymphocytic leukemia]. Hattori H; Kuwayama M; Kotake T; Karasuno T Gan To Kagaku Ryoho; 2011 Feb; 38(2):333-6. PubMed ID: 21368508 [TBL] [Abstract][Full Text] [Related]
9. BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR. Zagaria A; Anelli L; Coccaro N; Tota G; Casieri P; Cellamare A; Impera L; Brunetti C; Minervini A; Minervini CF; Delia M; Cumbo C; Orsini P; Specchia G; Albano F Virchows Arch; 2015 Sep; 467(3):357-63. PubMed ID: 26149409 [TBL] [Abstract][Full Text] [Related]
10. Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia. De Melo VA; Milojkovic D; Khorashad JS; Marin D; Goldman JM; Apperley JF; Reid AG Blood; 2007 Oct; 110(8):3086-7. PubMed ID: 17916757 [No Abstract] [Full Text] [Related]
11. Response to dasatinib in a patient with concomitant chronic myeloid leukemia and chronic lymphocytic leukemia. Serpa M; Bendit I; Seguro F; Xavier F; Cavalcante M; Steinbaum D; Nardinelli L; Aldred VL; de Paula HM; Dorlhiac-Llacer PE Acta Haematol; 2010; 124(2):105-9. PubMed ID: 20720403 [TBL] [Abstract][Full Text] [Related]
12. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147 [TBL] [Abstract][Full Text] [Related]
13. Management of Bcr-Abl-positive leukemias with dasatinib. Hochhaus A Expert Rev Anticancer Ther; 2007 Nov; 7(11):1529-36. PubMed ID: 18020922 [TBL] [Abstract][Full Text] [Related]
14. Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib. Loglisci G; Breccia M; Nanni M; Mancini M; De Cuia R; Cannella L; Salaroli A; Federico V; Serrao A; Loglisci MG; Santopietro M; Alimena G Leuk Lymphoma; 2011 Jul; 52(7):1372-5. PubMed ID: 21463110 [No Abstract] [Full Text] [Related]
15. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia. Abbott BL Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209 [TBL] [Abstract][Full Text] [Related]
16. Dasatinib in chronic myelogenous leukemia. Chu SC; Tang JL; Li CC N Engl J Med; 2006 Sep; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978 [No Abstract] [Full Text] [Related]
17. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. Soverini S; Martinelli G; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M J Clin Oncol; 2006 Nov; 24(33):e51-2. PubMed ID: 17114651 [No Abstract] [Full Text] [Related]
18. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group. Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131 [TBL] [Abstract][Full Text] [Related]
19. [Research advance on molecular genetics of CML blast crisis]. Zhu HQ; Zhang S; Liu XL Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935 [TBL] [Abstract][Full Text] [Related]